Rizatriptan for acute migraine

Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hou...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2001-07, Vol.2001 (3)
Main Authors: Oldman, Anna, Smith, Lesley A, McQuay, Henry J, Moore, R Andrew, Derry, Sheena
Format: Article
Language:English
Subjects:
Medicine General & Introductory Medical Sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Migraine is a significant health problem affecting about 18% of women and 6% of men, and many medicines are available for its treatment. This review assesses the effectiveness of rizatriptan (Maxalt) using data from 3710 patients with migraine. Significant pain relief was achieved within half‐an‐hour of taking one 10 mg dose of rizatriptan, (one hour for the 5 mg dose) and continued for at least 24 hours. There was insufficient information in the trial reports to enable meaningful comments to be made about side effects.
ISSN:1469-493X
DOI:10.1002/14651858.CD003221.pub2